Journal List > J Clin Neurol > v.14(4) > 1101813

Cao, Yang, Dong, Huang, Cao, and Yu: Secondary Short-Lasting Unilateral Neuralgiform Headache with Conjunctival Injection and Tearing: A New Case and a Literature Review

Abstract

Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) is a primary headache syndrome with an unclear pathogenesis. However, there is increasing evidence in the literature for secondary SUNCT being attributable to certain known lesions. We explored the possible neurobiological mechanism underlying SUNCT based on all reported cases of secondary SUNCT for which detailed information is available. Here we report a case of neuromyelitis optica spectrum disorders that had typical symptoms of SUNCT that might have been attributable to involvement of the spinal nucleus of the trigeminal nerve. We also review cases of secondary SUNCT reported in the English-language literature and analyze them for demographic characteristics, clinical features, response to treatment, and imaging findings. The literature review shows that secondary SUNCT can derive from a neoplasm, vascular disease, trauma, infection, inflammation, or congenital malformation. The pons with involvement of the trigeminal root entry zone was the most commonly affected region for inducing secondary SUNCT. In conclusion, the neurobiology of secondary SUNCT includes structures such as the nucleus and the trigeminal nerve with its branches, suggesting that some cases of primary SUNCT have underlying mechanisms that are related to existing focal damage that cannot be visualized.

INTRODUCTION

Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) is a primary headache syndrome mentioned in the third part [covering trigeminal autonomic cephalalgias (TACs)] of the International Classification of Headache Disorders, third edition, beta version (ICHD-IIIβ), and is characterized by moderate-to-severe strictly unilateral head pain. The condition is typically characterized by the occurrence of at least 20 attacks lasting 1–600 seconds that involve both ipsilateral conjunctival injection and lacrimation.1 However, the increasing number of cases of secondary SUNCT attributed to neoplasms, neurovascular compression, infection, inflammation, trauma, and congenital malformations suggests that SUNCT could be a secondary symptom.
Here we report a patient who had SUNCT attributed to demyelination. We also critically review published secondary SUNCT cases for which detailed information from magnetic resonance imaging (MRI) is available up to April 2017, and analyze their etiology and focus location. Through reviewing our own cases and all previously published cases, we aimed to summarize the location of lesions that are more likely to induce secondary SUNCT and identify the possible pathogenesis of secondary SUNCT.

METHODS

This study was conducted in two parts: 1) an assessment of a single case from our clinic and 2) a literature review. We defined secondary SUNCT as a SUNCT-like symptom with an etiology corresponding to the diagnosis of SUNCT and secondary headache in ICHD-IIIβ. The literature review was conducted using the online database PubMed. All papers published in English were searched using the terms SUNCT, secondary SUNCT, and systematic SUNCT (last performed in April 2017). References in the discovered papers were also systemically reviewed to identify additional cases published in other articles or abstracts. The inclusion criteria for the literature review were as follows: 1) diagnosis of SUNCT in accordance with ICHD-IIIβ1 and 2) detailed description of competing etiologies or secondary forms of SUNCT such as a neoplasm, vascular disease, or infection. The information extracted for each case included the following: 1) etiology, 2) age at onset, 3) sex, 4) duration, 5) frequency, 6) trigger, 7) pain side, 8) focus location in MRI/CT, and 9) effective treatment.
Some of the cases identified in the literature review might have been included multiple times due to the presence of repeated reports on them without this being indicated.

RESULTS

Case report

A previously healthy 29-year-old male developed paroxysmal vomiting lasting for 2 months, headache, and right-sided visual loss, and began walking unsteadily for approximately 15 days prior to his admission on October 13, 2016. More details of the medical history are provided in Figs. 1, 2, 3, 4.
His white blood cell count was 11.17×109/L (normal: 3.5– 10×109/L) and the neutrophil count was 0.736% (normal: 0.50–0.70%), which may have been due to the taking of corticosteroids. A lumbar puncture was performed on October 15. The pressure of the cerebrospinal fluid and its white blood cell count and protein level were 125 mmH2O, 12×106/L (normal: 0–10×106/L), and 628.9 mg/dL (normal: 150–400 mg/dL), respectively. The IgG level was 3.89 mg/dL (normal: 0.0–3.4 mg/dL), and no oligoclonal band was detected.
Treatment with 75 mg of oral indomethacin twice daily upon admission to our hospital had little effect. The treatment frequency was reduced slightly to less than once per hour without alleviation of the headache. After excluding tubercular and other infectious diseases, the patient was treated with 1 g of methylprednisolone daily for 3 days and 60 mg of oral prednisolone thereafter. The patient was ultimately diagnosed with SUNCT attributable to demyelination. The paroxysmal hemicranial headaches with autonomic features had ceased 2 days after starting steroid treatment, and his visual acuity had improved to 0.6 in the right eye and 0.8 in the left. The intraocular pressure had decreased to 19.2 mm Hg and 19.7 mm Hg in the right and left eyes, respectively.
His headache had disappeared but his vision was decreased again in February 2017. After performing several examinations we diagnosed neuromyelitis optica spectrum disorders (NMOSD)2 based on a positive test for serum aquaporin-4 antibody and the presence of standard clinical features of optic neuritis, and attributed his SUNCT-like condition to NMOSD.

Literature review

We summarized 69 cases of SUNCT-like conditions associated with certain etiologies in 62 English-language studies reported on from 1991 to 2017 and for which there were detailed descriptions of the clinical features and imaging results of the patients. These cases comprised 17 with neoplasm,3456789101112131415161718 35 with neurovascular disease,19202122232425262728293031323334353637383940414243 2 with trauma,4445 10 with infection,464748495051525354 3 with inflammatory disease,555657 and 2 with congenital malformation (Table 1, 2, and 3).5859

SUNCT secondary to neoplasm

Eleven of the cases were secondary to pituitary adenoma,37910111213141618 of which four were macroadenoma371618 and three were pituitary microadenoma.3911 The other six cases comprised leiomyosarcoma,5 pilocytic astrocytoma,4 epidermoid tumor,17 cyst,6 pulmonary metastases,8 and meningioma.15 MRI findings showed that five cases were located in the cavernous sinus, two in the pons, two in the ocular region, two in the carotid artery, and one in the frontotemporal area. Another six cases comprising three pituitary microadenomas and three pituitary adenomas showed no extension in MRI.

SUNCT secondary to neurovascular disease

Thirty cases were caused by neurovascular compression,192022 2425262728303132333435363940414243 four cases were due to cerebral infarction,23293738 and one case was due to cavernous angioma.21 MRI findings showed that 32 cases were at the pons level, including a case of left cerebellar infarction, while its ischemic penumbra was considered to involve the ascending spinothalamic tract and descending trigeminal fibers at or below their site of entry (and subsequent caudal passage) into the lateral pontine tegmentum. Three cases were located in the unilateral dorsolateral medulla with the possible involvement of the spinal nucleus of the trigeminal nerve.

SUNCT secondary to other etiologies

The cases with other etiologies showed scattered focus locations. The trauma areas included head and whiplash injuries. The infection areas covered the chronic sinusitis, ethmoid sinusitis, sphenoiditis, and orbital venous vasculitis, and included two cases of viral meningitis/meningoencephalitis and three of varicella-zoster virus infection. Inflammation included one case of neuromyelitis optica and two cases of multiple sclerosis, both of which were due to congenital malformation with skull abnormalities.

Focus location

According to the etiology classification (Table 4), the most common location of the neoplasm was the cavernous sinus (5/18), followed by the pons, ocular region, and carotid artery (each 2/18), and then the frontotemporal area (1/18). Moreover, another six cases of pituitary adenoma showed no extension out of the sellar space, one of which was a nonfunctioning adenoma associated with headaches that ceased after surgery or administering cabergoline. In cases with vascular disease, the pons (32/35) and medulla (3/35) were common locations at which SUNCT was induced. Six of the ten cases of infectious disease and both traumatic cases showed no abnormalities in imaging, while the focus in the other four cases of infection was in the cervical spinal cord, ocular region, maxillary sinus, and sphenoid sinus. Since the focal lesions were scattered throughout demyelinated areas, we only focused on the most likely locations such as the pons, medulla, and cervical spinal cord (two cases), and the ocular region (one case). The focal lesions were difficult to locate in the two cases of congenital malformation due to skull abnormalities, but the most likely location was the pons in both cases.
According to the classification of focus location (Table 5), the pons was the most common location where SUNCT-like syndrome was induced, and 32 cases were vascular diseases while 6 involved neoplasms, demyelination, and congenital malformations. The second most common locations were the medulla and cavernous sinus, each comprising five cases. The medulla accounted for three cases of vascular disease and two cases of demyelination, and the cavernous sinus was only involved in cases of neoplasm. The third and fourth most common locations were the ocular region (two cases with neoplasm and two with infection or demyelination) and cervical spinal cord (two cases with demyelination and one with infection), respectively. The carotid artery (two cases of neoplasm), frontotemporal area (one case of neoplasm), maxillary sinus (one case of infection), and sphenoid sinus (one case of infection) were less common locations. In addition, no lesions were detected in imaging investigations in six cases of infection and two of trauma, but two cases of infection showed narrowing of the superior ophthalmic vein and a higher temperature around the ipsilateral orbital region. Finally, the tumor did not extend to adjacent tissues in six cases of pituitary adenoma.

DISCUSSION

SUNCT is a primary headache classified as a TAC.1 However, increasing numbers of SUNCT cases with known etiology have been reported. The case included in the present study was diagnosed as secondary SUNCT since it fulfilled the ICHD-IIIβ diagnostic criteria for SUNCT and was attributable to NMOSD,2 which is a rare cause that has seldom been reported previously. The case with a left-sided headache had lesions on the contralateral cerebellopontine angle (CPA) and ipsilateral medulla. However, the lesion on the CPA appeared at least 2 months before the onset of the headache, and so we considered the lesion on the dorsolateral medullar to be the one responsible. Moreover, we summarized the focus locations of 69 cases that met the ICHD-IIIβ diagnosis criteria for SUNCT and were attributed to neoplasms, vascular disease, trauma, infection, inflammation, and congenital malformations, indicating that secondary SUNCT indeed exists. The exact pathogenesis of secondary SUNCT has not yet been well established, but our findings have revealed that there are certain main areas where SUNCT is induced.
The probable SUNCT-related trigeminal nerve conduction pathway60 is illustrated as follows (Fig. 5): First, the afferent pathways (sensory fibers) comprising the primary neurons of the trigeminal nerve are located in the trigeminal ganglion, with peripheral processes distributed among the head and facial, skin, oral, and nasal mucosa receptors. After entering the pons, nociceptive afferents of the central process terminate in subnuclei of the trigeminal brainstem nuclear complex. Some of the fibers of the secondary neurons in the nuclear complex and the gray matter of upper cervical spinal cord segments (C1 to C2) form the trigeminohypothalamic tract61 and then project to or go through the hypothalamus. The other fibers from the sensory and spinal nucleus of the trigeminal nerve cross upward, and the composite trigeminal lemniscus terminates in the ventral posteromedial nucleus of the thalamus, passing the posterior limb of the internal capsule and ending at the postcentral gyrus. Second, the efferent pathways (motor fibers) in the hypothalamus regulate lachrymal gland secretion. Parasympathetic fibers of the facial nerve are sent out by the superior salivatory nucleus and terminate in the pterygopalatine ganglion via the greater petrosal nerve. Postganglionic fibers of the pterygopalatine ganglion are distributed to the mucous membrane in the lachrymal gland, palate, and nosepiece, controlling the exudation of the mucous membrane and gland body.
Based on the conduction pathway and images in the literature, we assumed that three areas were mainly responsible for the induction of secondary SUNCT (Fig. 5): 1) the dorsolateral medulla and upper cervical spinal cord where the spinal nucleus of the trigeminal nerve is located (Shadow A in the Fig. 5), 2) the pons (Shadow B) in which vascular compression was likely to occur, and 3) the preganglionic fibers of the trigeminal nerve (Shadow C) that was the focus of neoplasm and widespread infection. Cases with cerebral infarction,23293738 infection,51 and demyelination5556 explicitly manifested in the Shadow-A area because they mainly exhibited lesions in the pons, dorsolateral medulla, and cervical spinal cord (C1 to C2) where the trigeminal divisions, trigeminal nucleus, spinothalamic tract, and trigeminohypothalamic tract are present and thus induce SUNCT. Neurovascular compression1920222425262728303132333435363940414243 was the most common reason in cases in the Shadow-B area, which could be clearly visualized using MRI and could accurately indicate vascular malformation in the CPA cistern that involves the trigeminal root entry zone and mostly irritates fibers of the first division (V1) of the trigeminal nerve and the greater petrosal nerve; thus, patients would present with accompanying conjunctival injection and tearing. However, there were more than 35 cases of neurovascular compression in our review. Williams and Broadley,40 Sebastian et al.60 and Favoni et al.36 reported other cases of SUNCT secondary to neurovascular compression that were excluded from our review due to a lack of detailed information.
In addition, there were focuses in the lateral cavernous sinus, frontotemporal region, maxillary sinus, sphenoid sinus, ocular region, and carotid sinus, and six cases of infection showed no abnormities on MRI/CT, while two of the cases exhibited narrowing of the superior ophthalmic vein46 and a higher temperature around the ipsilateral orbital region.50 These cases also have a high probability of developing invasion into the divisions of the trigeminal nerve because the focus of the neoplasm and infection can sometimes invade the intracranial and extracranial structures associated with pain sensitivity. These include the endocranium and divisions of the trigeminal nerve (frontal, lachrymal, and nasociliary nerves of the ophthalmic, maxillary, and mandibular nerves) that cannot be seen clearly in images, which was inevitably the actual causal lesion for secondary SUNCT. However, six cases of pituitary adenoma showed a focus in the sellar region without extending to the adjacent tissue. These cases comprised three of microadenoma, another three for which the tumor size was not stated explicitly, and one that was a nonfunctioning tumor. Although the pathophysiology of pituitary-associated headache is not well understood, and most authors have suspected it to be related to abnormalities in the hypothalamic-pituitary endocrine system, we still primarily attributed the effect to unseen cadaverous sinus invasion, dural stretching, or local pressure effects because the nonsecreting tumor case10 represented negative evidence that SUNCT-like headaches can also occur when hormone levels are normal. In other words, pain in the V1 area may to some extent arise from pressure or stretching of the first division of the trigeminal nerve adjacent to the cavernous sinus, whereas other nerves such as the oculomotor, trochlear, and abducent nerves will be not involved due to the limitations of the pressure.
Regarding the associated symptoms such as conjunctival injection and tearing, we inferred that the lesions indicated by Shadows B and C in Fig. 5 had mostly invaded the first division of the trigeminal nerve with distribution of the parasympathetic nerve fiber in the mucous membrane in the lachrymal gland. However, due to the conduction pathway being unknown, we only determined that the trigeminal autonomic symptoms were related to the salivary nucleus and could not elucidate how lesions in Shadow-A areas could induce conjunctival injection and tearing.
Our search of the references revealed that the secondary causes for SUNCT can also reportedly cause trigeminal neuralgia and other TACs. For example, vascular compression can induce short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms-like headache36 that is associated with conjunctival injection or lacrimation. Chiari malformation type I,62 focal cervical myelitis,63 diffuse large-B-cell lymphoma of the nasopharynx,64 and upper cervical meningioma65 can induce cluster-like headache, whose lesions were similar to those of SUNCT. Although our extensive literature search did not reveal a feasible mechanism to indicate the difference, we speculate that affected anatomical structures are the main reason.
Secondary SUNCT will occur with damage to the nucleus, tracts, and peripheral nerves, and the possibility of secondary symptoms cannot be excluded in primary cases with normal imaging findings because some focal damage cannot be visualized using current imaging methods. We have illustrated that certain aspects of SUNCT might be a secondary symptom. When encountering patients with SUNCT in the clinical situation, the best option for physicians is to perform MRI scans with high-resolution sequences of basal cisterna and pituitary fossa sections.

CONCLUSION

We have presented a special case of secondary SUNCT with demyelination. We also reviewed all reported cases of secondary SUNCT in the English-language literature since this condition was first reported in 1991, and analyzed its etiology, focus location, and pain laterality. Finally, we hypothesized three mechanisms for secondary SUNCT and assumed that some aspects of this condition might be a secondary symptom, although some lesions cannot be visualized.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (grants 81471147, 81671077, 81471146, 81500966, 81500943, and 81600952), Beijing Science and Technology Project (grant Z16110000 2616013), the Capital Development Scientific Research (grant 2014-4-5013), and Beijing Natural Science Foundation (grant 7162178).

Notes

Conflicts of Interest: The authors have no financial conflicts of interest.

References

1. Headache Classification Committee of the International Headache Society (IHS).The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 2013; 33:629–808. PMID: 23771276.
2. Tan CT, Mao Z, Qiu W, Hu X, Wingerchuk DM, Weinshenker BG. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2016; 86:491–492. PMID: 26833940.
3. Massiou H, Launay JM, Levy C, El Amrani M, Emperauger B, Bousser MG. SUNCT syndrome in two patients with prolactinomas and bromocriptine-induced attacks. Neurology. 2002; 58:1698–1699. PMID: 12058109.
crossref
4. Blättler T, Capone Mori A, Boltshauser E, Bassetti C. Symptomatic SUNCT in an eleven-year-old girl. Neurology. 2003; 60:2012–2013. PMID: 12821758.
crossref
5. Kaphan E, Eusebio A, Donnet A, Witjas T, Chérif A. Shortlasting, unilateral, neuralgiform headache attacks with conjunctival injection and tearing (SUNCT syndrome) and tumour of the cavernous sinus. Cephalalgia. 2003; 23:395–397. PMID: 12780771.
crossref
6. Lim EC, Teoh HL. Headache - it's more than meets the eye: orbital lesion masquerading as SUNCT. Cephalalgia. 2003; 23:558–560. PMID: 12950384.
crossref
7. Matharu MS, Levy MJ, Merry RT, Goadsby PJ. SUNCT syndrome secondary to prolactinoma. J Neurol Neurosurg Psychiatry. 2003; 74:1590–1592. PMID: 14617728.
crossref
8. Black D, Swanson J, Eross E, Cutrer FM. Secondary SUNCT due to intraorbital, metastatic bronchial carcinoid. Cephalalgia. 2005; 25:633–635. PMID: 16033391.
crossref
9. Leroux E, Schwedt TJ, Black DF, Dodick DW. Intractable SUNCT cured after resection of a pituitary microadenoma. Can J Neurol Sci. 2006; 33:411–413. PMID: 17168168.
crossref
10. Rocha Filho PA, Galvão AC, Teixeira MJ, Rabello GD, Fortini I, Calderaro M, et al. SUNCT syndrome associated with pituitary tumor: case report. Arq Neuropsiquiatr. 2006; 64:507–510. PMID: 16917628.
crossref
11. Rozen TD. Resolution of SUNCT after removal of a pituitary adenoma in mild acromegaly. Neurology. 2006; 67:724. PMID: 16924039.
crossref
12. Jiménez Caballero . SUNCT syndrome in a patient with prolactinoma and cabergoline-induced attacks. Cephalalgia. 2007; 27:76–78. PMID: 17212687.
crossref
13. de Lourdes Figuerola M, Bruera O, Pozzo MJ, Leston J. SUNCT syndrome responding absolutely to steroids in two cases with different etiologies. J Headache Pain. 2009; 10:55–57. PMID: 19020800.
crossref
14. Zidverc-Trajkovic J, Vujovic S, Sundic A, Radojicic A, Sternic N. Bilateral SUNCT-like headache in a patient with prolactinoma responsive to lamotrigine. J Headache Pain. 2009; 10:469–472. PMID: 19763771.
crossref
15. Kutschenko A, Liebetanz D. Meningioma causing gabapentin-responsive secondary SUNCT syndrome. J Headache Pain. 2010; 11:359–361. PMID: 20428918.
crossref
16. Musuka TD, Edis RH, Kermode AG. Short-lasting unilateral neuralgiform headache with conjunctival injection and tearing caused by a pituitary adenoma. J Clin Neurosci. 2013; 20:1180–1181. PMID: 23664408.
crossref
17. Rodgers SD, Marascalchi BJ, Strom RG, Huang PP. Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing syndrome secondary to an epidermoid tumor in the cerebellopontine angle. Neurosurg Focus. 2013; 34:E1.
crossref
18. Berk T, Silberstein S. Case report: secondary SUNCT after radiation therapy--a novel presentation. Headache. 2016; 56:397–401. PMID: 26643474.
crossref
19. Bussone G, Leone M, Dalla Volta G, Strada L, Gasparotti R, Di Monda V. Short-lasting unilateral neuralgiform headache attacks with tearing and conjunctival injection: the first “symptomatic” case? Cephalalgia. 1991; 11:123–127. PMID: 1889067.
crossref
20. Morales F, Mostacero E, Marta J, Sanchez S. Vascular malformation of the cerebellopontine angle associated with “SUNCT” syndrome. Cephalalgia. 1994; 14:301–302. PMID: 7954761.
crossref
21. De Benedittis G. SUNCT syndrome associated with cavernous angioma of the brain stem. Cephalalgia. 1996; 16:503–506. PMID: 8933996.
crossref
22. Gardella L, Viruega A, Rojas H, Nagel J. A case of a patient with SUNCT syndrome treated with Jannetta procedure. Cephalalgia. 2001; 21:996–999. PMID: 11843874.
crossref
23. Penart A, Firth M, Bowen JR. Short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT) following presumed dorsolateral brainstem infarction. Cephalalgia. 2001; 21:236–239. PMID: 11442560.
crossref
24. Köseoglu E, Karaman Y, Kücük S, Arman F. SUNCT syndrome associated with compression of trigeminal nerve. Cephalalgia. 2005; 25:473–475. PMID: 15910575.
crossref
25. Lagares A, Gómez PA, Pérez-Nuñez A, Lobato RD, Ramos A. Short-lasting unilateral neuralgiform headache with conjunctival injection and tearing syndrome treated with microvascular decompression of the trigeminal nerve: case report. Neurosurgery. 2005; 56:E413. PMID: 15670392.
crossref
26. Sprenger T, Valet M, Platzer S, Pfaffenrath V, Steude U, Tolle TR. SUNCT: bilateral hypothalamic activation during headache attacks and resolving of symptoms after trigeminal decompression. Pain. 2005; 113:422–426. PMID: 15661452.
crossref
27. Zidverc-Trajkovic J, Mijajlovic M, Pavlovic AM, Jovanovic Z, Sternic N. Vertebral artery vascular loop in SUNCT and concomitant trigeminal neuralgia. case report. Cephalalgia. 2005; 25:554–557. PMID: 15955046.
crossref
28. Mondéjar B, Cano EF, Pérez I, Navarro S, Garrido JA, Velásquez JM, et al. Secondary SUNCT syndrome to a variant of the vertebrobasilar vascular development. Cephalalgia. 2006; 26:620–622. PMID: 16674773.
crossref
29. Rodrigues GG, Bordini CA, Dach F, Eckeli A, Speciali JG. SUNCT syndrome: report of a possible symptomatic case. Arq Neuropsiquiatr. 2007; 65:852–854. PMID: 17952296.
crossref
30. Guerreiro R, Casimiro M, Lopes D, Marques JP, Fontoura P. Video NeuroImage: symptomatic SUNCT syndrome cured after trigeminal neurovascular contact surgical decompression. Neurology. 2009; 72:e37. PMID: 19221289.
crossref
31. Irimia P, González-Redondo R, Domínguez PD, Díez-Valle R, Martínez-Vila E. Microvascular decompression may be effective for refractory SUNCT regardless of symptom duration. Cephalalgia. 2010; 30:626–630. PMID: 19614700.
crossref
32. Williams M, Bazina R, Tan L, Rice H, Broadley SA. Microvascular decompression of the trigeminal nerve in the treatment of SUNCT and SUNA. J Neurol Neurosurg Psychiatry. 2010; 81:992–996. PMID: 20462914.
crossref
33. Bartsch T, Falk D, Knudsen K, Reese R, Raethjen J, Mehdorn HM, et al. Deep brain stimulation of the posterior hypothalamic area in intractable short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT). Cephalalgia. 2011; 31:1405–1408. PMID: 21628443.
crossref
34. Chaila E, Ali E, Rawluk D, Hutchinson M. ‘Switching off’ SUNCT by sudden head movement: a new symptom. J Neurol. 2011; 258:694–695. PMID: 21072534.
crossref
35. Paliwal VK, Singh P, Kumar A, Rahi SK, Gupta RK. Short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT) with preserved refractory period: report of three cases. J Headache Pain. 2012; 13:167–169. PMID: 22227716.
crossref
36. Favoni V, Grimaldi D, Pierangeli G, Cortelli P, Cevoli S. SUNCT/ SUNA and neurovascular compression: new cases and critical literature review. Cephalalgia. 2013; 33:1337–1348. PMID: 23800827.
37. Jin D, Lian YJ, Zhang HF. Secondary SUNCT syndrome caused by dorsolateral medullary infarction. J Headache Pain. 2016; 17:12. PMID: 26885826.
crossref
38. Lambru G, Trimboli M, Tan SV, Al-Kaisy A. Medullary infarction causing coexistent SUNCT and trigeminal neuralgia. Cephalalgia. 2017; 37:486–490. PMID: 27226002.
crossref
39. Kitahara I, Fukuda A, Imamura Y, Ikawa M, Yokochi T. Pathogenesis, surgical treatment, and cure for SUNCT syndrome. World Neurosurg. 2015; 84:1080–1083. PMID: 26008143.
crossref
40. Williams MH, Broadley SA. SUNCT and SUNA: clinical features and medical treatment. J Clin Neurosci. 2008; 15:526–534. PMID: 18325769.
crossref
41. Coskun O, Ucar M, Vuralli D, Yildirim F, Cetinkaya R, Akin Takmaz S, et al. MR tractography in short lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) patients: case reports. Pain Med. 2017; 18:1377–1381. PMID: 28339630.
crossref
42. Ertsey C, Bozsik G, Afra J, Jelencsik I. A case of SUNCT syndrome with neurovascular compression. Cephalalgia. 2000; 20:325.
43. Maggioni F, Manara R, Mampreso E, Viaro F, Mainardi F, Zanchin G. Trigeminal neuralgia and trigeminal-autonomic cephalalgias: a continuum or simple co-existence? Cephalalgia. 2010; 30:752–756. PMID: 19624686.
crossref
44. Putzki N, Nirkko A, Diener HC. Trigeminal autonomic cephalalgias: a case of post-traumatic SUNCT syndrome? Cephalalgia. 2005; 25:395–397. PMID: 15839855.
crossref
45. Choi HJ, Choi SK, Lee SH, Lim YJ. Whiplash injury-induced atypical short-lasting unilateral neuralgiform headache with conjunctival injection and tearing syndrome treated by greater occipital nerve block. Clin J Pain. 2012; 28:342–343. PMID: 22330130.
crossref
46. Hannerz J, Greitz D, Hansson P, Ericson K. SUNCT may be another manifestation of orbital venous vasculitis. Headache. 1992; 32:384–389. PMID: 1399559.
crossref
47. Bichuetti DB, Yamaoka WY, Bastos JR, Carvalho Dde S. Bilateral SUNCT syndrome associated to chronic maxillary sinus disease. Arq Neuropsiquiatr. 2006; 64:504–506. PMID: 16917627.
crossref
48. Eguia P, Garcia-Monco JC, Ruiz-Lavilla N, Diaz-Konrad V, Monton F. SUNCT and trigeminal neuralgia attributed to meningoencephalitis. J Headache Pain. 2008; 9:51–53. PMID: 18217200.
crossref
49. Choi JY, Seo WK, Kim JH, Oh K, Yu SW. Symptomatic SUNCT syndrome associated with ipsilateral paranasal sinusitis. Headache. 2008; 48:1527–1530. PMID: 19076651.
crossref
50. Ito Y, Yamamoto T, Ninomiya M, Mizoi Y, Itokawa K, Tamura N, et al. Secondary SUNCT syndrome caused by viral meningitis. J Neurol. 2009; 256:667–668. PMID: 19444540.
crossref
51. Cascella C, Rosen JB, Robbins MS, Levin M. Resident and fellow section. teaching case: symptomatic SUNCT. Headache. 2011; 51:1022–1026. PMID: 21631490.
52. Pong DL, Marom T, Pine HS. Short-lasting unilateral neuralgiform headache attacks with conjunctiva injection and tearing presenting as sphenoiditis. Am J Otolaryngol. 2013; 34:166–168. PMID: 23201466.
crossref
53. Granato A, Belluzzo M, Fantini J, Zorzon M, Koscica N. SUNCT-like syndrome attributed to varicella-zoster virus meningoencephalitis. Neurol Sci. 2015; 36:807–808. PMID: 25073697.
crossref
54. Mathew T, Srinivas M, Badachi S, Nadig R. Post herpes zoster SUNCT like syndrome: insights from two case reports. Cephalalgia. 2018; 38:399–401. PMID: 27799443.
crossref
55. Kursun O, Arsava EM, Oguz KK, Tan E, Kansu T. SUNCT associated with Devic's syndrome. Cephalalgia. 2006; 26:221–224. PMID: 16426279.
crossref
56. Vilisaar J, Constantinescu CS. SUNCT in multiple sclerosis. Cephalalgia. 2006; 26:891–893. PMID: 16776709.
crossref
57. Bogorad I, Blum S, Green M. A case of MS presenting with SUNCT status. Headache. 2010; 50:141–143. PMID: 19751367.
crossref
58. ter Berg JW, Goadsby PJ. Significance of atypical presentation of symptomatic SUNCT: a case report. J Neurol Neurosurg Psychiatry. 2001; 70:244–246. PMID: 11160478.
crossref
59. Morís G, Ribacoba R, Solar DN, Vidal JA. SUNCT syndrome and seborrheic dermatitis associated with craneosynostosis. Cephalalgia. 2001; 21:157–159. PMID: 11422101.
crossref
60. Sebastian S, Schweitzer D, Tan L, Broadley SA. Role of trigeminal microvascular decompression in the treatment of SUNCT and SUNA. Curr Pain Headache Rep. 2013; 17:332. PMID: 23564233.
crossref
61. Zhang X. Trigeminohypothalamic tract. In : Gebhart GF, Schmidt RF, editors. Encyclopedia of Pain. 2nd ed. Berlin: Springer-Verlag Berlin Heidelberg;2013. p. 4082.
62. Kao YH, Hsu YC. Chiari malformation type I presenting as clusterlike headache. Acta Neurol Taiwan. 2015; 24:122–124. PMID: 27333966.
63. Kim DE, Park JY, Ha H, Yoon GJ, Cho BH, Lee SH. Cluster-like headache secondary to focal cervical myelitis. Neurologist. 2017; 22:138–140. PMID: 28644256.
crossref
64. Budhram A, Leung A, Sangle N, Khaw AV. Diffuse large B-cell lymphoma of the nasopharynx presenting with cluster-like headache. Headache. 2017; 57:806–808. PMID: 28295284.
crossref
65. Kuritzky A. Cluster headache-like pain caused by an upper cervical meningioma. Cephalalgia. 1984; 4:185–186. PMID: 6498932.
crossref
Fig. 1

Medical history. AQP4-ab: aquaporin-4 antibody, CSF: cerebrospinal fluid, MBP-ab: myelin basic protein antibody, MRI: magnetic resonance imaging.

jcn-14-433-g001
Fig. 2

MRI performed on August 9 showed slightly long T1-weighted (A), and T2-weighted (B) values for the splenium of the corpus callosum (arrowheads) with a high diffusion-weighted-imaging signal (C), and equal T1 signal (D), slightly high T2 (E), and T2 Flair values (F) for the right middle cerebellar peduncle (arrowheads).

jcn-14-433-g002
Fig. 3

Enhanced lesion on October 16 located near the left ventral medulla (arrowhead) in axis (A) and extended from the dorsolateral of lower medulla oblongata to the C1 level (arrowhead) in the sagittal position (B).

jcn-14-433-g003
Fig. 4

MRI in May showed the enhanced lesion in the optic nerve (arrowheads) of the right eye (A and B), while the left side was normal (C).

jcn-14-433-g004
Fig. 5

Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing-related pathways and structures. Shadow A represents the dorsolateral medulla and upper cervical spinal cord where the spinal nucleus of the trigeminal nerve was located, which was often affected by cerebral infarction and demyelination. Vascular compression was likely to occur in the area of Shadow B. The neoplasm and infection had a widespread focus, and were mostly located at the preganglionic fibers of the trigeminal nerve (Shadow C).

jcn-14-433-g005
Table 1

Clinical features of 17 patients with short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing attributed to neoplasm

jcn-14-433-i001
Disease Patient no. Age at onset (years) Sex Duration (seconds) Frequency (per day) Trigger Pain side Focus location in MRI/CT Effective treatment
Pituitary macroadenoma 17 26 M 20–30 1–6 Yes R R cavernous sinus and carotid artery BCT
216 33 M 10 1–10 Yes L L cavernous sinus DA
318 35 F 60–120 40 Yes R R cavernous carotid artery LMT
43 27 F 15–30 N/A Yes L L cavernous sinus Radiotherapy
Pituitary adenoma 513 46 M 15–120 3–6 Yes L L cavernous sinus CAB
612 22 F <60 5–10 Yes L No extension CAB
7*10 26 M 60 2–8 N/A L No extension Surgery
814 18 F 30 5–10 No B No extension LMT
Pituitary microadenoma 93 24 F 15–30 10–30 Yes L No extension Surgery
109 28 M 20–30 100–200 N/A R No extension Surgery
1111 33 M 60–120 30 N/A L No extension Surgery
Leiomyosarcoma 125 45 M 60–120 10–15 Yes L L cavernous sinus N/A
Pilocytic astrocytoma 134 11 F 30–60 20 No R R pons–CPA Surgery
Epidermoid tumor 1417 33 M 30–60 240 Yes L L pons–CPA Surgery
Cyst 156 23 F 10–60 20–30 Yes R R ocular region Surgery
Pulmonary metastases 168 69 F 60–120 50–70 Yes R R ocular region Radiotherapy
Meningioma 1715 81 F N/A 60 No L L frontotemporal infiltrative growing GBP

*Nonfunctioning adenoma.

BCT: bromocriptine, CAB: cabergoline, CPA: cerebellopontine angle, CT: computed tomography, DA: dopamine, GBP: gabapentin, LMT: lamotrigine, MRI: magnetic resonance imaging, N/A: not applicable.

Table 2

Clinical features of 35 patients with short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing attributed to vascular disease

jcn-14-433-i002
Disease Patient no. Age at onset (years) Sex Duration (seconds) Frequency (per day) Trigger Pain side Focus location in MRI/CT Effective treatment
Neurovascular compression 1819 33 M 30 360 No L L pons–CPA–arteriovenous malformation CBZ
1920 55 M 30 280–360 Yes R R pons–CPA–vascular malformation CBZ, AMT
2022 43 F 30–45 6–7 Yes R R pons–PCC–SCA MVD
2125 54 F 60–120 N/A Yes L L pons–PCC–SCA MVD
2226 47 M 60 30–40 Yes R R pons–PCC–SCA MVD
2333 67 M 1–60 <720 Yes R R pons–PCC–SCA DBS
2434 45 F Seconds 20–60 Yes L L pons–PCC–SCA MVD
2536 44 M 30–60 >20 Yes R R pons–PCC–SCA OXA, LMT
2630 57 M 30–120 120–240 N/A L L pons–PCC–SCA VL MVD
2731 54 M 5–10 3–10 Yes L L pons–PCC–SCA VL MVD
2832,40 65 F 60–180 30–200 Yes R R pons–PCC–SCA VL MVD
2932 65 M 60–120 30–200 Yes R R pons–SCA N/A
3032,40 43 M 30–120 20–30 No L L pons–AICA LMT, lignocaine
3132,40 46 F 3–10 90–120 Yes R R pons–SCA LMT, lignocaine
3232 44 F 30–120 100–300 Yes N/A Pons–SCA N/A
3332,40 19 M 20–180 8–10 Yes L L pons–SCA LMT
3435 60 M 20–30 20–50 Yes R R pons–PCC–SCA VL OXA, LMT
3535 55 M 10–90 25–30 Yes R R pons–SCA VL LMT
3635 64 M 10–30 5–30 Yes R B pons–SCA VL CBZ
3736 46 M 30–60 1–6 Yes R R pons–SCA VL CBZ, IM
3836 50 F 2–180 >100 Yes R R pons–SCA VL MVD
3924 48 M 20–30 15–20 Yes L L pons–AICA None
4027 68 M 60–120 3–7 N/A L L pons–BA VL GBP
4128 55 M 30 20–30 No L L pons–vertebrobasilar None
4239 52 M 360 N/A Yes R R pons–PCC–VA MVD
4339 65 M Seconds N/A N/A R R pons–PCC–SCA, AICA MVD
4441 46 F 60–120 N/A Yes R R pons–PCC–SCA MVD
4541 69 F 120–180 N/A Yes R R pons–PCC–SCA CBZ
4642 43 F 30–45 6–7 Yes R R pons–SCA MVD
4743 40 F <300 2–30 Yes R R pons–SCA LMT, GBP, amitriptyline
Cerebellar infarction 4823 63 M 20–180 8 Yes L L pons–ischemic–penumbra of cerebellar N/A
4929 54 M 20 10 No R R dorsolateral medulla None
5037 64 M 3–10 1–4 No L L dorsolateral medulla N/A
5138 58 M 20 12–15 Yes R R dorsolateral medulla CBZ, GBP
Cavernous angioma 5221 60 M 60 15–23 N/A L L pons CBZ

AICA: anterior inferior cerebellar artery, AMT: amitriptyline, BA: basilar artery, CBZ: carbamazepine, CPA: cerebellopontine angle, CT: computed tomography, DBS: deep brain stimulation, GBP: gabapentin, IM: indomethacin, LMT: lamotrigine, MRI: magnetic resonance imaging, MVD: microvascular decompression, N/A: not applicable, OXA: oxcarbazepine, PCC: pontocerebellar cistern, SCA: superior cerebellar artery, VA: vertebral artery, VL: vascular loop.

Table 3

Clinical features of 17 patients with short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing attributed to other etiologies

jcn-14-433-i003
Disease Patient no. Age at onset (years) Sex Duration (seconds) Frequency (per day) Trigger Pain side Focus location in MRI/CT Effective treatment
Head injury 5344 20 M 20–60 160 Yes R None CBZ
Whiplash injury 5445 62 F 120–240 40–50 Yes R None GON blocks
Sinusitis 5547 53 M 5–10 144 Yes L>R B maxillary sinuses FESS
Ethmoid sinusitis 5649 71 M 3–5 >100 N/A R R ocular region FESS
Sphenoiditis 5752 62 F 60–240 >20 N/A R R sphenoid sinus AMX–clavulanate
Orbital venous vasculitis 5846 49 M 300–600 1–180 Yes R None* Steroids, AZA
Viral meningitis 5950 49 M 10 100–200 N/A R None Sumatriptan
VZV meningoencephalitis 6048 46 F 30–60 240 No R None VPA
6153 72 M 10–60 20–40 Yes R None GBP
VZV 6254 58 M 20 96–120 Yes R None Pregabalin, LMT
6354 60 M 10–60 120 N/A L None Pregabalin
6451 57 F 5–30 50–100 No L Cervical spinal cord (C2/C3, C5/C6) GBP
NMO 6555 41 F 10–15 20 N/A L>R Medulla to cervical spinal cord (C6); ocular region MP, IVIg
MS 6656 18 M 5–30 20 N/A R R medulla; pons; cervical spinal cord. N/A
6757 59 F Seconds 720 N/A L L pons Steroids, CMZ, IM
Osteogenesis imperfecta 6858 42 M 120–180 1–5 Yes L Basilar impression; L pons CBZ
Craniosynostosis brachycephaly 6959 14 F 60 50 Yes R Foreshortened posterior fossa; more notable in the R pons–CPA CBZ, PDN, lithium carbonate

*Narrowing of superior ophthalmic vein, Thermogram showed that the skin temperature was higher around the orbital region than around the left side, suggesting decreased right sympathetic nerve function, CT scans were normal when headache started. The author considered them to be a peripheral mechanism.

AMX: amoxicillin, AZA: azathioprine, CBZ: carbamazepine, CMZ: carbimazole, CPA: cerebellopontine angle, CT: computed tomography, FESS: functional endoscopic sinus surgery, GBP: gabapentin, GON: greater occipital nerve, IM: indomethacin, IVIg: intravenous immunoglobulin, MP: methylprednisolone, MRI: magnetic resonance, MS: multiple sclerosis, N/A: not applicable, NMO: neuromyelitis optica, PDN: prednisone, VPA: valproic acid, VZV: varicella-zoster virus.

Table 4

Distribution of lesion locations according to the etiology classification

jcn-14-433-i004
Variable n (%)
Neoplasm (n=18)
 No extension 6 (33.33)
 Cavernous sinus 5 (27.78)
 Pons 2 (11.11)
 Ocular region 2 (11.11)
 Carotid artery 2 (11.11)
 Frontotemporal area 1 (5.56)
Vascular disease (n=35)
 Pons 32 (91.43)
 Medulla 3 (8.57)
Trauma (n=2)
 None 2 (100)
Infection (n=10)
 None 6 (60)
 Maxillary sinus 1 (10)
 Ocular region 1 (10)
 Sphenoid sinus 1 (10)
 Cervical spinal cord 1 (10)
Demyelination* (n=3)
 Pons 2 (66.67)
 Medulla 2 (66.67)
 Cervical spinal cord 2 (66.67)
 Ocular region 1 (33.33)
Congenital malformation (n=2)
 Pons 2 (100)

*Demyelination had multiple focuses, each of which could be the lesion responsible for inducing short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing.

Table 5

Distribution of etiology according to the classification of lesion location

jcn-14-433-i005
Location n (%)
Pons (n=38)
 Vascular disease 32 (84.22)
 Neoplasm 2 (5.26)
 Demyelination 2 (5.26)
 Congenital malformation 2 (5.26)
Medulla (n=5)
 Vascular disease 3 (60)
 Demyelination 2 (40)
Cavernous sinus (n=5)
 Neoplasm 5 (100)
Ocular region (n=4)
 Neoplasm 2 (50)
 Infection 1 (25)
 Demyelination 1 (25)
Cervical spinal cord (n=3)
 Demyelination 2 (66.67)
 Infection 1 (33.33)
Carotid artery (n=2)
 Neoplasm 2 (100)
Frontotemporal area (n=1)
 Neoplasm 1 (100)
Maxillary sinus (n=1)
 Infection 1 (100)
Sphenoid sinus (n=1)
 Infection 1 (100)
None (n=8)
 Infection 6 (75)
 Trauma 2 (25)
No extension (n=6)
 Neoplasm 6 (100)
TOOLS
Similar articles